1.22CNY
1.33 BCNY
10.09 BCNY
367.87 M
About CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD.
Sector
Headquarters
Beijing
Employees (FY)
12.27 K
Website
Founded
1997
ISIN
CNE000000Q94
FIGI
BBG000BJD4G5
China Resources Double-Crane Pharmaceutical Co., Ltd. engages in the processing, manufacture, and sale of pharmaceutical, chemical, and biomedical raw materials. It operates through the following business segments: Infusion and Non-infusion. Its products include compound reserpine flattamine tablets, amlodipine besylate tablets, gliquidone tablets, citicoline sodium tablets, magnesium valproate sustained-release tablets, and soft bags. The company was founded on May 16, 1997 and is headquartered in Beijing, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 600062 is 20.99 CNY — it has decreased by 1.55% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. stocks are traded under the ticker 600062.
CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. is going to release the next earnings report on Apr 26, 2024. Keep track of upcoming events with our Earnings Calendar.
600062 stock is 3.03% volatile and has beta coefficient of 1.63. Check out the list of the most volatile stocks — is CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. there?
600062 earnings for the last quarter are 0.31 CNY per share, whereas the estimation was 0.21 CNY resulting in a 49.37% surprise. The estimated earnings for the next quarter are 0.24 CNY per share. See more details about CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. earnings.
CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. revenue for the last quarter amounts to 2.63 B CNY despite the estimated figure of 1.80 B CNY. In the next quarter revenue is expected to reach 2.15 B CNY.
Yes, you can track CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. financials in yearly and quarterly reports right on TradingView.
600062 stock has risen by 0.62% compared to the previous week, the month change is a 0.77% rise, over the last year CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. has showed a 0.91% increase.
600062 net income for the last quarter is 300.97 M CNY, while the quarter before that showed 404.36 M CNY of net income which accounts for −25.57% change. Track more CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. financial stats to get the full picture.
Today CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. has the market capitalization of 22.09 B, it has decreased by 0.54% over the last week.
CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. dividend yield was 1.38% in 2023, and payout ratio reached 19.77%. The year before the numbers were 3.23% and 50.72% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 600062 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 12.27 K employees. See our rating of the largest employees — is CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. stock shows the strong buy signal. See more of CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. future price: according to them, 600062 price has a max estimate of 26.00 CNY and a min estimate of 23.00 CNY. Read a more detailed CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. forecast: see what analysts think of CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. EBITDA is 1.91 B CNY, and current EBITDA margin is 20.93%. See more stats in CHINA RESOURCES DOUBLE－CRANE PHARMACEUTICAL CO.,LTD. financial statements.